Biomarkers associated with atherogenesis: current status and promising areas

Por M. A. Magruk, A. A. Mosikyan, A. Yu. Babenko
Publicado em 2019-12-01

Cost-effectiveness analysis of ixabepilone use in monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and...

Por A S Kolbin, A A Mosikyan, Y E Balykina, M A Proskurin
Publicado em 2018-03-01

Budget impact analysis: principles of good practice. Report of the ISPOR Working Group on Good Practices for Budget Impact Analysis II, 2012

Por Sean D. Sullivan, Josephine A. Mauskopf, Federico Augustovski, J. Jaime Caro, Karen M. Lee, Mark Minchin, Ewa Orlewska, Pete Penna, Jose-Manuel Rodriguez Barrios, Wen-Yi Shau, T. L. Galankin, A. A. Mosikyan, A. S. Kolbin
Publicado em 2018-05-01